JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Additional Paid In Capital
JW (Cayman) Therapeutics Co Ltd
Additional Paid In Capital Peer Comparison
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Additional Paid In Capital
¥6.1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
172%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Additional Paid In Capital
¥81.4B
|
CAGR 3-Years
15%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Additional Paid In Capital
¥27.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Additional Paid In Capital
¥3.3B
|
CAGR 3-Years
95%
|
CAGR 5-Years
81%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Additional Paid In Capital
¥48m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-29%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Additional Paid In Capital
¥3.4B
|
CAGR 3-Years
190%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
6.1B
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Additional Paid In Capital amounts to 6.1B CNY.
What is JW (Cayman) Therapeutics Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
172%
Over the last year, the Additional Paid In Capital growth was 0%.